Ship an Auditable Pharmacogenomics ETL in 90 Days for Labs

The minimum viable deliverable for any ETL for pharmacogenomics is a harmonized, provenance-tagged dataset that links patient genotype to medication history through canonical identifiers and CPIC or DPWG rules, exportable as FHIR DiagnosticReport resources and knowledge-graph triples. The architecture behind it needs five layers: ingestion, harmonization and ID mapping, variant/star-allele consensus, QC with audit logging, and an analytic store or knowledge graph feeding EHR delivery. Every layer needs human review checkpoints and version-aware processing, or the output isn't clinically defensible.

TL;DR:

• Accurate star-allele calling requires multi-caller consensus and normalization steps to prevent false diplotype assignments, especially for copy-number variation genes like CYP2D6.
• Maintaining strict version control, provenance tagging, and temporal validation ensures pipeline reproducibility, clinical defensibility, and correct guideline application.
• Mapping genetic and drug data to canonical vocabularies like HGNC, RxNorm, MeSH, and ChEBI through staged exact and fuzzy matching prevents silent record fragmentation.
• Delivery of PGx results into clinical systems relies on HL7 FHIR DiagnosticReports, GA4GH VRS objects, and real-time CDS Hooks to support clinicians at point-of-care while safeguarding data security.
• Using scalable ETL tools like Spark with Glow, combined with rigorous audit logging and versioning, enables pipelines to handle large cohorts efficiently and remain audit-ready over time.

Table of Contents

• What Does ETL for Pharmacogenomics Actually Require?
• How Do You Map PGx Data to Canonical Identifiers?
• How Do You Go From VCF to a Clinical Star-Allele Call?
• How Do You Keep a PGx Pipeline Auditable Over Time?
• Should You Build a Knowledge Graph or a Relational Store?
• How Do You Deliver PGx Results Into Clinical Systems?
• What Tools Actually Scale for Pharmacogenomics ETL?
• How Do You Prepare PGx ETL Outputs for Machine Learning?
• How Does SignalPGx Fit This ETL Architecture?
• A 90-Day Checklist for Standing Up Your Pipeline
• Where to Find Implementation-Ready Resources
• Get a PGx Reporting Pipeline Without Building One From Scratch
• The Gap Between Academic Prototypes and Clinical Production
• Sources
• FAQ

What Does ETL for Pharmacogenomics Actually Require?

Pharmacogenomics data integration is unlike standard clinical ETL because the "truth" moves. CPIC guidelines get revised, allele definitions get updated, and a diplotype call correct in 2023 can be wrong under a 2026 nomenclature revision. Your pipeline has to treat every fact as versioned, not static.

Inputs typically span three very different data shapes. From the EHR, you're pulling structured domains: medication orders and fills, problem lists, lab results, encounter timestamps. From the lab side, you're ingesting VCF files (occasionally PLINK or BGEN for research cohorts) containing raw genotype calls. And from the knowledge layer, you're pulling curated PGx resources like PharmGKB, ClinVar, SIDER, and Reactome, which supply the drug-gene-phenotype relationships that turn a genotype into a clinical recommendation.

Outputs need to satisfy three different consumers at once: a feature table for downstream analytics or machine learning, a FHIR DiagnosticReport for the EHR, and, increasingly, knowledge-graph edges for hypothesis generation and drug repurposing research. A large-scale pharmacogenomic knowledge graph built for drug-gene-variant-disease discovery illustrates why: once PharmGKB, ClinVar, SIDER, and Reactome are harmonized to controlled vocabularies, the same underlying dataset supports both clinical lookups and multi-hop research queries.

Success criteria for the pipeline itself come down to five things:

• Interoperability — outputs map cleanly to HGNC, RxNorm, MeSH, and ChEBI so joins across sources don't silently fail.
• Provenance — every record carries its source, version, and extraction timestamp, not just its value.
• Temporal integrity — no downstream model or report can accidentally use information published after the point it claims to represent.
• Reproducibility — the same raw inputs, run twice, produce the same diplotype calls and the same recommendation.
• Clinical defensibility — a medical director can trace any output back through the transform logic to its source evidence.

Privacy and regulatory constraints shape the architecture from day one rather than getting bolted on later. HIPAA and GDPR both treat genetic data as sensitive, which means your ingestion and storage layers need encryption at rest and in transit, strict access controls, and audit logging baked into the pipeline design, not layered on after a security review flags a gap. Think of these as engineering constraints on your schema and infrastructure choices, not a legal sign-off you get at the end.

How Do You Map PGx Data to Canonical Identifiers?

Semantic reconciliation is where most PGx integration projects quietly fail. A gene referenced as "CYP2D6" in one source, "cytochrome P450 2D6" in another, and by an outdated alias in a third will silently produce three disconnected records instead of one, unless you enforce canonical IDs at the mapping layer.

The standard approach uses four controlled vocabularies, each solving a specific mapping problem:

• HGNC for gene symbols and identifiers, resolving synonyms and deprecated names to a single current symbol.
• RxNorm for medications, normalizing brand names, generic names, and dosage forms to one clinical drug concept.
• MeSH for phenotypes and clinical conditions, giving you a hierarchy you can roll up or drill down through.
• ChEBI for chemical entities, useful when a drug's mechanism (rather than its brand name) matters for a downstream rule.

The mapping workflow itself typically runs in stages rather than a single pass. Build an id_maps table first, a static lookup that resolves known synonyms and aliases to canonical IDs, sourced from each vocabulary's own cross-reference files. Run exact-match joins against that table before anything else; this alone should resolve the large majority of records. For what's left, fuzzy string matching (Levenshtein distance or a phonetic algorithm) against the canonical name list catches typos and minor variant spellings, but every fuzzy match needs a confidence score attached, not a silent accept. Anything below your confidence threshold routes to a manual curation queue rather than getting auto-accepted, because a wrong gene-to-drug mapping is worse than a missing one. And every resolved record needs a mapping provenance field recording which method resolved it (exact match, fuzzy match, or manual curation) and when.

• Build a static id_maps cross-reference table from each vocabulary's own release files.
• Run exact-match resolution first; it should clear most of the volume.
• Apply fuzzy matching with an explicit confidence score for the remainder, never a silent accept.
• Route low-confidence matches to manual curation, not an automatic default.
• Log the resolution method and timestamp on every mapped record.

For cross-source reconciliation at scale, ontology-driven approaches using RDF and OWL start to earn their complexity. When you're joining PharmGKB's gene-drug pairs against ClinVar's variant classifications against Reactome's pathway data, brittle SQL joins on string-matched names break constantly as source vocabularies drift. i2b2/tranSMART's guidance on ontology-driven integration argues for letting investigators query across integrated clinical and genomic data through a flexible ontology layer rather than hardcoded joins, and the same logic applies to PGx-KG-style pipelines. RDF triples let you express "this variant is-a allele-of this gene, which metabolizes this drug class" once, then reuse that relationship across every downstream query without re-deriving it. Ontology-driven integration work in bioinformatics makes the same case for reconciling fragmented PGx relationships specifically, where semantic web techniques outperform manual join logic once you're past a handful of source databases.

How Do You Go From VCF to a Clinical Star-Allele Call?

Turning raw genotype calls into a diplotype a physician can act on runs through three distinct stages, and skipping any one of them produces calls that look plausible and are wrong.

Normalization comes first. Liftover resolves genome-build mismatches (GRCh37 versus GRCh38 references are still common in the wild). Left-alignment and multiallelic splitting break compound VCF records into the atomic representation that variant callers expect. Skip normalization and you'll see the same physical variant represented three different ways across three source files, none of which match each other in a downstream join.

Multi-caller consensus is the step that separates a research pipeline from a clinical one. No single star-allele caller handles every gene reliably; CYP2D6 in particular requires copy-number-variant detection that trips up tools not built for it. PRISM-PGx, a production-grade multi-caller pipeline, combines PharmCAT, Aldy, and Cyrius (with Stargazer as an optional fourth) into an evidence-weighted consensus score rather than trusting any single caller's output. When two callers agree and a third disagrees, the consensus model down-weights the outlier instead of averaging blindly, and CNV-heavy genes get flagged for closer review rather than an automatic pass.

• Run liftover and normalization before any caller sees the data.
• Never ship a single-caller diplotype for CYP2D6, CYP2C19, or other CNV-prone genes without a consensus check.
• Weight caller agreement by each tool's known reliability profile for that specific gene, not a flat vote.
• Flag low-consensus calls for manual review instead of auto-resolving to the majority caller.

Output formats need to satisfy both machine and human consumers. A consensus TSV or JSON file gives you a machine-readable record for the analytic store. An HL7 FHIR DiagnosticReport gives the EHR something it can render for a clinician. GA4GH VRS objects give you a standardized, versioned representation of the variant itself, useful when you need to reference the exact allele definition used at call time rather than a name that might mean something different next year. And every consensus call needs an audit artifact recording which callers ran, what they returned individually, and how the consensus model resolved disagreement.

Glow's ETL utilities handle the normalization and liftover steps at scale for teams processing cohort-level VCF volumes, which matters once you're past a few hundred samples and a single-node script stops finishing overnight.

How Do You Keep a PGx Pipeline Auditable Over Time?

Quality control in pharmacogenomics data analysis runs at two levels, per-sample and cohort-wide, and both need explicit thresholds rather than eyeballed sanity checks.

At the sample level, coverage depth and phase confidence are the two numbers that matter most. A star-allele call built on low-coverage regions or ambiguous phasing (where you can't tell which alleles sit on which chromosome) needs a confidence flag attached before it ever reaches a report. At the cohort level, you're watching for batch effects, unexpected allele frequency shifts between sequencing runs, and call-rate drops that suggest a technical problem rather than a biological one.

Temporal integrity is the QC dimension most teams underweight until it causes a real problem. A pipeline evaluated against CPIC guidance published after the training data's cutoff date will look more accurate than it actually is in production, because it's effectively been given the answer key. Leakage-aware processing for PGx knowledge graphs recommends three specific controls to prevent this:

1. Version metadata tagging on every knowledge source ingested, so any downstream consumer can filter to "what was known as of date X."
2. Publication-date audits run before any model training or validation split, checking that no record in the training set was published after the stated cutoff.
3. Chronological train/validation/test splits, rather than random splits, so a model's reported performance reflects what it would have known at deployment time, not retroactive knowledge.

Human-in-the-loop checkpoints close the loop between automated QC and clinical accountability. Every automated transform that touches a diplotype call or a drug-gene recommendation should emit a review artifact, not just a log line. A medical-director oversight model described in a PGx decision-support prototype treats exceptions (low-confidence calls, conflicting caller outputs, guideline updates that change a prior recommendation) as items requiring explicit sign-off before they reach a patient-facing report, rather than letting the pipeline auto-publish.

Pro Tip: Build your audit log schema before you build your transforms, not after. Retrofitting audit trails onto an existing pipeline almost always means gaps in exactly the records regulators or medical directors will ask about first.

Should You Build a Knowledge Graph or a Relational Store?

The choice between a knowledge graph and a relational store isn't either/or for most clinical-grade pipelines. It's a question of which workload you're optimizing first.

Relational stores (or Delta Lake for the versioned, ACID-compliant variant) win for cohort analytics and feature-table generation. If your primary use case is "give me a table of every patient with a CYP2D6 poor-metabolizer phenotype currently on a contraindicated SSRI," a well-indexed relational schema answers that query fast and predictably. Knowledge graphs win when the question is multi-hop and exploratory: "what drugs metabolized by genes in this pathway have documented interactions with this patient's current medication list, and what's the evidence trail for each." A PGx-KG-style dataset built from harmonized PharmGKB, ClinVar, SIDER, and Reactome data, complete with nodes, edges, and ID maps, exists specifically because that second kind of query is nearly impossible to express cleanly in SQL once you're past three or four joins.

Whichever model you choose, certain schema elements aren't optional:

• Source provenance on every node or row: which database, which version, which extraction date.
• Confidence or evidence level on every relationship or fact, not just a binary present/absent flag.
• Temporal validity windows, so a fact can be marked as accurate for a specific date range rather than eternally true.
• Cross-reference IDs back to the canonical vocabularies (HGNC, RxNorm, MeSH, ChEBI) so the record can be joined against future data without re-running mapping logic.

Hybrid architectures are increasingly the practical answer rather than a compromise. Run your relational or Delta Lake store as the system of record for clinical reporting and feature generation, and maintain a knowledge graph as a downstream, periodically synchronized view for research and hypothesis generation. The synchronization job itself becomes another ETL pipeline, one that reads from the relational store's change log and writes graph edges, which means it inherits the same provenance and versioning discipline as everything upstream of it.

How Do You Deliver PGx Results Into Clinical Systems?

Getting a diplotype call from your analytic store into a clinician's workflow runs through a small set of interoperability standards that have become the de facto default for pharmacogenomics data management in production settings.

HL7 FHIR R4 is the backbone. A DiagnosticReport resource carries the overall genotype summary and its associated CPIC or DPWG recommendation, while individual Observation resources carry the specific variant or diplotype findings that support it. This separation matters because a clinician's EHR view typically renders the DiagnosticReport summary first, with the supporting Observations available on drill-down, mirroring how a lab report reads in practice.

GA4GH VRS objects handle the variant representation itself, giving you a standardized way to reference "this exact allele, as defined by this exact nomenclature version" that survives a future guideline revision without ambiguity. Pairing FHIR for clinical delivery with VRS for variant precision is quickly becoming standard practice across production multi-caller pipelines.

CDS Hooks is where living reanalysis becomes operationally real. Rather than waiting for a clinician to open a static report, a CDS Hooks service can fire at the moment of prescribing, checking the patient's stored genotype against the drug being ordered and surfacing a warning or dosing adjustment in real time. Refresh strategy matters here: a nightly batch reconciliation against updated CPIC guidance is usually sufficient for report content, but the CDS Hooks service itself needs to query current recommendation state on every prescribing event, not a cached snapshot that might be a guideline revision behind.

• Use FHIR DiagnosticReport for the clinician-facing summary, Observation resources for the supporting detail.
• Represent variants with GA4GH VRS objects rather than free-text allele names.
• Fire CDS Hooks at the point of prescribing, querying live recommendation state rather than a cached report.
• Encrypt genotype and medication data at rest and in transit, and log every access for HIPAA and GDPR accountability.
• Scope EHR integration credentials tightly. A PGx delivery service needs read access to orders and results, not blanket chart access.

Security and compliance considerations aren't a separate workstream from integration; they're a design constraint on it. Every FHIR endpoint your pipeline talks to needs authenticated, scoped access, and every genotype record that crosses that boundary needs to carry only the fields the receiving system actually needs. That's as much an architecture decision as a policy one.

What Tools Actually Scale for Pharmacogenomics ETL?

Tool choice for ETL tools for genomics depends almost entirely on where you sit on the scale curve, and picking a Spark cluster for a 50-sample prototype is as wrong as picking a single SQL script for a 500,000-sample production cohort.

For prototypes and low-volume clinical workflows, a SQL Server plus .NET stack, similar to the approach used in a VA-linked decision-support prototype, handles the EHR-to-genotype join and CPIC rule matching without the operational overhead of a distributed system. This is the right starting point for most teams validating a pipeline design before committing to infrastructure.

Once variant volume grows past what a single database instance can comfortably process, Apache Spark with Glow becomes the standard tool for genomics data processing at scale. Glow's documentation covers variant normalization, liftover, and utilities for merging variant datasets across cohorts, functions that would otherwise require custom bioinformatics scripting for every pipeline stage. Its ETL module specifically handles the VCF, BGEN, and PLINK ingestion patterns that a relational-only stack struggles with at cohort scale.

Delta Lake sits underneath Spark/Glow for teams that need reproducible, versioned analytic storage. Its transaction log gives you point-in-time queries, meaning you can reconstruct exactly what your dataset looked like before a CPIC guideline update, without maintaining separate snapshot files.

Orchestration matters as much as the processing engine itself:

• Use Airflow or Dagster to schedule and monitor multi-stage pipelines, not cron jobs with ad hoc logging.
• Write unit tests for every transform function, especially ID mapping and consensus scoring logic, where a silent regression is hardest to catch downstream.
• Version every pipeline artifact (code, configuration, and the knowledge-source snapshot it ran against) so a report generated last quarter can be regenerated identically if a medical director asks for a re-derivation.
• Run integration tests against a fixed sample dataset after every pipeline change, checking that known diplotype calls still resolve correctly.

Cost and performance trade-offs are real but predictable. A Spark cluster costs more to run idle than a SQL Server instance, so the crossover point is usually somewhere around the volume where manual query tuning on the relational side starts eating more engineering time than the cluster costs to operate.

How Do You Prepare PGx ETL Outputs for Machine Learning?

Feature engineering for pharmacogenomics ML models starts with the same harmonized dataset your clinical reports use, but the shape it needs to take is different, and skipping that reshaping step is where a lot of otherwise solid pipelines produce misleading models.

Useful feature examples include diplotype flags (categorical, one per gene of interest), CPIC-level exposure windows (has this patient been on a CYP-substrate medication for longer than the guideline's recommended monitoring period), and aggregated medication histories aligned to the genotype's collection date rather than the report's generation date. That last alignment detail matters more than it sounds: a medication started after the genotype sample was drawn shouldn't be treated as evidence available at the moment the model is trying to predict.

Labeling and leakage prevention follow the same temporal discipline covered under QC, but applied specifically to model training:

• Label outcomes using only information that was actually available at the prediction time point, not retrospective knowledge.
• Tag every knowledge source (CPIC version, PharmGKB snapshot) used to generate a feature with its version, so you can audit exactly what the model saw.
• Build train, validation, and test splits chronologically rather than randomly, mirroring the leakage-aware processing approach used in PGx knowledge-graph construction.

Model evaluation for clinical deployment needs metrics that mean something to a physician, not just a data scientist. Sensitivity for detecting actionable gene-drug interactions matters more than raw accuracy, given how skewed the class distribution typically is (most patients don't carry an actionable variant for most drugs). Explainability tools like SHAP or a tree-based explainer let you show which features drove a specific prediction, which is close to a requirement if the model's output is going to influence a clinical recommendation rather than sit in a research notebook. Set acceptance thresholds before you see results, not after, or you'll rationalize a marginal model into production.

How Does SignalPGx Fit This ETL Architecture?

Every layer covered in this playbook, ingestion, harmonization, consensus calling, QC, and delivery, maps directly onto how SignalPGx is built for clinical laboratories deploying pharmacogenomics data management infrastructure.

• Ingestion and harmonization: SignalPGx integrates genotype data, medication histories, and clinical evidence from more than 20 sources, running the same canonical-ID mapping discipline (HGNC, RxNorm, and equivalent vocabularies) described earlier in this piece.
• Living reanalysis: as CPIC and DPWG guidance updates, SignalPGx re-evaluates existing patient records against the new rule set automatically, the same version-aware reprocessing this article argues is non-negotiable for temporal integrity. Read more about how living PGx reports keep recommendations current as guidelines shift.
• HL7/FHIR integration: outputs deliver into EHRs using the same DiagnosticReport and CDS Hooks patterns covered above, detailed further in how FHIR and CDS Hooks deliver PGx guidance at the point of prescribing.
• Human-in-the-loop review: every report includes medical-director review and an audit trail before delivery, matching the checkpoint model this guide recommends at the consensus and QC stages.
• Compliance: the platform operates under HIPAA and GDPR controls at the infrastructure level, not as an afterthought layered onto an existing pipeline.

For labs that don't want to build this stack from scratch, SignalPGx's white-label infrastructure lets a laboratory launch a branded PGx reporting service typically within 5 to 7 days, drawing on infrastructure already built around the architecture this article describes. The genotype-to-guidance pipeline walks through how those pieces connect end to end.

A 90-Day Checklist for Standing Up Your Pipeline

If you're starting from zero, sequence your first 90 days around proving the architecture works before scaling it. Weeks 1 through 3: build a source catalog listing every EHR domain, VCF format, and knowledge database you'll ingest, with version and refresh cadence for each. Weeks 4 through 8: stand up a small-scale, multi-caller consensus pipeline on a handful of well-characterized samples, PharmCAT plus one other caller is enough to prove the consensus logic. Weeks 9 through 11: run a CPIC mapping test against real medication histories to confirm your ID mapping resolves cleanly before you scale sample volume. Weeks 12 through 13: ship a FHIR delivery proof of concept into a sandbox EHR instance.

The pitfall I see most often isn't technical, it's sequencing. Teams build the knowledge graph before they've validated that their star-allele consensus is reliable, which means they end up re-processing the entire graph once the consensus logic changes. Validate calling accuracy first. Everything downstream depends on it, and nothing downstream fixes it.

Treat this checklist as a starting frame, not a finished spec; every lab's EHR quirks will force adjustments the first time real data hits the pipeline.

Where to Find Implementation-Ready Resources

A handful of resources let you go from reading this playbook to running actual code. Glow's documentation covers the Spark-based ETL utilities for variant normalization and Delta Lake construction at scale, with runnable examples for VCF and BGEN ingestion. PRISM-PGx is a cloneable, production-grade multi-caller consensus pipeline you can run against your own VCF samples to see evidence-weighted star-allele calling in practice. The PGx-KG dataset on Zenodo gives you a processed, ingestible knowledge graph (nodes, edges, triples, and ID maps) for benchmarking your own harmonization logic against a known-good reference. And the Frontiers prototype study documents the SQL-based ETL design and medical-director oversight model referenced throughout this guide. Clone the repos, run the sample pipelines against synthetic data first, and validate your own transforms against their published outputs before trusting them on real patient records.

Get a PGx Reporting Pipeline Without Building One From Scratch

Everything in this playbook, consensus calling, canonical mapping, version-aware QC, FHIR delivery, is engineering work your lab either builds in house over months or deploys through infrastructure already built to that specification. SignalPGx gives laboratories the second path: white-label PGx reporting infrastructure that handles ingestion, harmonization, medical-director review, and EHR delivery, deployable under your lab's own brand typically within 5 to 7 days instead of a multi-quarter build.

For a lab that has read this far and is now weighing "build our own ETL stack" against "deploy proven infrastructure," the calculation usually comes down to time and audit risk. A homegrown pipeline needs its own consensus logic, its own version-tracking discipline, and its own compliance review before it ever touches a patient record. SignalPGx's white-label PGx reporting platform already runs that architecture in production, with HIPAA and GDPR compliance built into the infrastructure layer rather than bolted on after deployment.

If your lab is evaluating whether to build or deploy, book a demo to see how the platform maps to the architecture covered in this guide, or check current plans to scope what a launch would look like for your patient volume.

The Gap Between Academic Prototypes and Clinical Production

Most published pharmacogenomics ETL work, including the strongest prototypes referenced throughout this piece, proves a concept on a research cohort and stops there. That's not a criticism; it's a mismatch of goals. A research pipeline needs to demonstrate that adding genetic variables improves prediction. A clinical pipeline needs to survive a medical director's audit, a guideline revision, and a regulator's question about why a specific patient got a specific recommendation eighteen months ago.

The uncomfortable truth is that the hardest parts of clinical-grade PGx ETL are the parts that don't show up in a benchmark paper: the manual curation queue for low-confidence ID mappings, the audit log schema that has to anticipate questions nobody's asked yet, and the discipline to build chronological validation splits when a random split would have made your model look better on paper. Teams that skip straight to knowledge-graph construction because it sounds more sophisticated than a well-QC'd relational store often end up rebuilding that store six months later, once someone asks why a report can't be traced back to a specific guideline version.

If there's one piece of conventional wisdom worth pushing back on, it's the idea that more sources and more sophisticated tooling automatically produce a better pipeline. A pipeline built on three well-versioned, well-mapped sources with a rigorous consensus and audit process will outperform one built on ten poorly reconciled sources every time a real clinical question gets asked of it. Start narrow, get the provenance and versioning discipline right, and expand sources only once that foundation holds.

— Tarek

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

Sources

Every clinical-grade pipeline pulls from the same handful of source categories, but the file formats and refresh cadence differ enough to break naive ingestion scripts.

EHR extracts usually arrive as HL7 v2 messages, C-CDA documents, or FHIR R4 bundles, depending on how modern the source system is. Genotype data comes as VCF files from clinical sequencing panels, occasionally supplemented by PLINK or BGEN formats from research-grade genotyping arrays. Curated knowledge sources, PharmGKB, ClinVar, SIDER, and Reactome, ship as periodic bulk dumps (TSV, XML, or RDF depending on the source) rather than live APIs, which means your pipeline needs a deliberate refresh schedule rather than real-time polling.

Ingestion has to preserve three things that are trivially easy to lose: the source version, a checksum proving the file wasn't corrupted or truncated in transit, and an immutable copy of the raw payload before any transformation touches it.

• Pharmacogenomics driven decision support prototype with machine learning: A framework for improving patient care | Frontiers in Big Data
• A Large-Scale Pharmacogenomic Knowledge Graph for Drug-Gene-Variant-Disease Discovery | medRxiv
• glbala87/PRISM-PGx
• Pharmacogenomic Knowledge Graph (PGx-KG): Processed Dataset for Link Prediction — Zenodo

Pro Tip: Keep raw, untransformed extracts for at least one full guideline revision cycle. When CPIC updates a dosing recommendation, you'll want to re-run historical genotypes against the new rule set without re-pulling data from the EHR.

For EHR connectivity specifically, you're choosing between streaming and bulk patterns. FHIR subscriptions or HL7 v2 ADT feeds give you near-real-time updates on new lab results or medication orders, which matters if you're running living reanalysis that needs to react to a new prescription within hours. Bulk FHIR exports (using the $export operation) are better suited to full-cohort backfills or nightly batch reconciliation, where throughput matters more than latency.

An ETL framework built around a VA-linked pharmacogenomics decision-support prototype used SQL Server routines to integrate diagnosis codes, medication fills, and genotype results into a single analyzable dataset, and found that adding genetic variables meaningfully improved prediction of preventable adverse drug events. That result depended entirely on getting the EHR-to-genotype join right at the ingestion stage.

Provenance tagging isn't optional metadata bureaucracy. When a physician asks why a report flagged a drug interaction, "PharmGKB version 2025.3, CPIC guideline dated August 2025" is the difference between a defensible answer and a shrug.

FAQ

What Is the Difference Between ETL for Pharmacogenomics and Standard Clinical ETL?

Standard clinical ETL moves relatively stable structured data like lab results and diagnosis codes. ETL for pharmacogenomics has to additionally reconcile genotype calls from multiple variant callers, map them to versioned clinical guidelines like CPIC, and preserve full provenance because a diplotype's clinical meaning can change when guidelines update.

Why Is Multi-Caller Consensus Necessary for Star-Allele Calling?

No single star-allele caller handles every gene reliably, particularly CNV-heavy genes like CYP2D6. Combining multiple callers, as PRISM-PGx does, into an evidence-weighted consensus catches disagreements a single-caller pipeline would silently miss.

How Do You Prevent Temporal Leakage in PGx Machine Learning Models?

Tag every knowledge source with version metadata, audit publication dates before training, and build chronological rather than random train/validation/test splits so a model never trains on guidance published after its stated prediction date.

Which Vocabularies Should PGx ETL Pipelines Map To?

HGNC for gene identifiers, RxNorm for medications, MeSH for phenotypes, and ChEBI for chemical entities are the standard canonical vocabularies used to make PGx data interoperable across sources.

Can SignalPGx Replace a Custom-Built PGx ETL Pipeline?

SignalPGx provides white-label infrastructure covering ingestion, harmonization, medical-director review, and FHIR-based EHR delivery, letting labs deploy a clinical-grade pharmacogenomics reporting pipeline without building each layer from scratch.

Recommended

• How Labs Launch a PGx Reporting Service
• Build vs Buy: PGx Reporting for Labs
• Why Lab PGx Programs Stall - and Launch Faster
• From Genotype to Guidance: The PGx Pipeline